CY1124456T1 - Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων - Google Patents

Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων

Info

Publication number
CY1124456T1
CY1124456T1 CY20211100758T CY211100758T CY1124456T1 CY 1124456 T1 CY1124456 T1 CY 1124456T1 CY 20211100758 T CY20211100758 T CY 20211100758T CY 211100758 T CY211100758 T CY 211100758T CY 1124456 T1 CY1124456 T1 CY 1124456T1
Authority
CY
Cyprus
Prior art keywords
drug conjugates
antibody drug
antibodies
antigen
human
Prior art date
Application number
CY20211100758T
Other languages
English (en)
Inventor
Miranda Maria Cornelia Van Der Lee
Gerardus Joseph Andreas ARIAANS
Jan SCHOUTEN
Marion Blomenrohr
Patrick Gerhard GROOTHUIS
Rudy Gerardus Elisabeth Coumans
Original Assignee
Byondis B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byondis B.V. filed Critical Byondis B.V.
Publication of CY1124456T1 publication Critical patent/CY1124456T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Η παρούσα αποκάλυψη σχετίζεται με αντισώματα καθορισμένα από CDR που στοχεύουν στο ογκοφυλλοειδές αντιγόνο 5Τ4 (TPBG, 5T4, Wnt Activated Inhibitory Factor 1, WAIF1) που εμφανίζουν δεσμευτική συγγένεια για το ανθρώπινο αντιγόνο 5Τ4 το οποίο είναι στην ίδια τάξη μεγέθους με τη συγγένεια τους με τον πίθηκο cynomolgus 5T4. Αξιώνονται συζεύματα φαρμάκου αντισωμάτων (ADC) και η χρήση τους στη θεραπεία ανθρώπινων στερεών όγκων και αιματολογικών κακοηθειών.
CY20211100758T 2015-11-24 2021-08-25 Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων CY1124456T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15195978 2015-11-24
EP16191272 2016-09-29
PCT/EP2016/078642 WO2017089447A1 (en) 2015-11-24 2016-11-24 Anti-5t4 antibodies and antibody-drug conjugates

Publications (1)

Publication Number Publication Date
CY1124456T1 true CY1124456T1 (el) 2022-07-22

Family

ID=57406227

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100758T CY1124456T1 (el) 2015-11-24 2021-08-25 Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων

Country Status (23)

Country Link
US (2) US11008400B2 (el)
EP (1) EP3380122B1 (el)
JP (1) JP6914956B2 (el)
KR (1) KR20180083425A (el)
CN (1) CN108348608B (el)
AU (1) AU2016358854B2 (el)
BR (1) BR112018010394A8 (el)
CA (1) CA3005294A1 (el)
CL (1) CL2018001334A1 (el)
CY (1) CY1124456T1 (el)
DK (1) DK3380122T3 (el)
ES (1) ES2889398T3 (el)
HR (1) HRP20211280T1 (el)
HU (1) HUE055482T2 (el)
LT (1) LT3380122T (el)
MX (1) MX2018006372A (el)
MY (1) MY187325A (el)
PL (1) PL3380122T3 (el)
RU (1) RU2736720C2 (el)
SG (1) SG11201803692PA (el)
TW (1) TWI744261B (el)
WO (1) WO2017089447A1 (el)
ZA (1) ZA201802584B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831976A (zh) * 2017-05-23 2020-02-21 斯索恩生物制药有限公司 用于制备抗体-药物缀合物的双重缀合方法
AU2018304173A1 (en) 2017-07-17 2020-01-30 Janssen Biotech, Inc. Antigen binding regions against fibronectin type III domains and methods of using the same
CN108187065B (zh) * 2017-12-29 2023-04-28 广东众生药业股份有限公司 抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途
MA52152A (fr) * 2018-03-12 2021-01-20 Genmab As Anticorps
CN117843795A (zh) * 2019-03-11 2024-04-09 凯惠科技发展(上海)有限公司 一种含半胱氨酸的抗体、药物偶联物及其应用
CN111499746B (zh) * 2020-04-28 2020-11-24 优睿赛思(武汉)生物科技有限公司 一种针对人白介素-2的高亲和力兔单克隆抗体及其应用
WO2023155925A1 (en) * 2022-02-21 2023-08-24 Concept To Medicine Biotech Co., Ltd. Anti-5t4 antibodies and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007947A1 (en) 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
PA8645301A1 (es) 2004-09-10 2006-07-03 Wyeth Corp Anticuerpo anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
EP1791565B1 (en) * 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
DK1994055T3 (da) 2006-03-10 2014-08-25 Wyeth Llc Anti-5t4-antistoffer og anvendelser deraf
UA112291C2 (uk) * 2010-04-21 2016-08-25 Синтарґа Б.В. Кон'югати аналогів cc-1065 і біфункціональні лінкери
CA2830338C (en) * 2011-04-01 2016-11-15 Wyeth Llc Antibody-drug conjugates
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
HUE056023T2 (hu) * 2014-05-22 2022-01-28 Byondis Bv Kapcsolt drogok helyspecifikus konjugációja ellenanyagokhoz, és a kapott ADC-k
US11008057B2 (en) * 2015-10-22 2021-05-18 Komatsu Ltd. Track link and link mounted part
CN110831976A (zh) * 2017-05-23 2020-02-21 斯索恩生物制药有限公司 用于制备抗体-药物缀合物的双重缀合方法

Also Published As

Publication number Publication date
MX2018006372A (es) 2018-09-05
US11008400B2 (en) 2021-05-18
ZA201802584B (en) 2022-12-21
RU2736720C2 (ru) 2020-11-19
JP2018538368A (ja) 2018-12-27
MY187325A (en) 2021-09-22
AU2016358854A1 (en) 2018-05-10
PL3380122T3 (pl) 2021-12-13
US11584801B2 (en) 2023-02-21
BR112018010394A8 (pt) 2019-02-26
HUE055482T2 (hu) 2021-11-29
BR112018010394A2 (pt) 2018-11-21
CA3005294A1 (en) 2017-06-01
EP3380122B1 (en) 2021-06-02
ES2889398T3 (es) 2022-01-12
EP3380122A1 (en) 2018-10-03
AU2016358854B2 (en) 2023-02-02
HRP20211280T1 (hr) 2021-11-12
DK3380122T3 (da) 2021-07-05
TWI744261B (zh) 2021-11-01
CN108348608A (zh) 2018-07-31
KR20180083425A (ko) 2018-07-20
RU2018122629A3 (el) 2020-04-27
CN108348608B (zh) 2022-02-08
RU2018122629A (ru) 2019-12-26
US20210317231A1 (en) 2021-10-14
SG11201803692PA (en) 2018-06-28
TW201731879A (zh) 2017-09-16
LT3380122T (lt) 2021-10-11
JP6914956B2 (ja) 2021-08-04
CL2018001334A1 (es) 2018-12-21
WO2017089447A1 (en) 2017-06-01
US20190194346A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
CY1124456T1 (el) Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων
CY1121907T1 (el) Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1120471T1 (el) Αντισωματα κατα του cd70
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
PH12016500781A1 (en) Novel anti-claudin antibodies and methods of use
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
EA201892294A1 (ru) Антитела и композиции против tim-3
EA202091540A1 (ru) Антитела к lilrb2
EA201591801A1 (ru) Лекарственные конъюгаты антител
PH12016501109A1 (en) Novel anti-dpep3 antibodies and methods of use
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
BR112017027254A2 (pt) anticorpos anti-cd123 e conjugados e derivados dos mesmos
EA201591072A1 (ru) Антитела против pdgfr-бета и их применения
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
MX2016008667A (es) Inmunoglobulina con fab en tandem y usos de esta.
ECSP13012402A (es) Inmunoglobulinas con dominio variable dual y su uso
UA112416C2 (uk) Антитіло до fap і способи його застосування
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
CL2019002953A1 (es) Anticuerpo anti-pd-l1 y uso del mismo.
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
WO2015153997A3 (en) Notch3 antibodies and uses thereof